The Ross Prize has been awarded to immunotherapy pioneers Carl June and Michel Sadelain, recognizing their transformative work in developing CAR T-cell therapies. The prize, given by the Ross Foundation, honors biomedical scientists whose discoveries have fundamentally changed medical practice.
June and Sadelain are widely credited with advancing chimeric antigen receptor (CAR) T-cell technology, which reprograms a patient's own immune cells to target and destroy cancers. Their collaborative and individual efforts over decades laid the groundwork for the first FDA-approved CAR T treatments, which have shown remarkable efficacy in certain blood cancers.
Clinical data from pivotal trials demonstrated complete remission rates exceeding 80% in some pediatric acute lymphoblastic leukemia patients. However, the therapy carries significant risks, including cytokine release syndrome and neurotoxicity, which require careful management.
The Ross Prize comes as CAR T research expands into solid tumors and autoimmune diseases. Both June and Sadelain have emphasized the need for persistence in the face of early skepticism and technical hurdles. Sadelain noted that "perseverance and persistence" were critical to overcoming initial failures.
Despite the success, challenges remain in improving manufacturing costs and extending the therapy's reach to more patients. Critics point to the multi-hundred-thousand-dollar price tag per infusion and the need for specialized treatment centers as barriers to widespread access.